Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 24, 2025
Lead Product(s) : Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Shanghai ShouYan Clinical Development Co.,Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pirfenidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Shanghai ShouYan Clinical Development Co.,Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pirfenidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Shanghai ShouYan Clinical Development Co.,Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pirfenidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2024
Lead Product(s) : Pirfenidone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Shanghai ShouYan Clinical Development Co.,Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lacosamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Beijing Capton Pharmaceutical Technology Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lacosamide is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Lacosamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Beijing Capton Pharmaceutical Technology Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ibuprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 15, 2023
Lead Product(s) : Amlodipine Besylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Health Start Pharmaceutical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amlodipine Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 29, 2022
Lead Product(s) : Amlodipine Besylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Health Start Pharmaceutical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brivaracetam
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : GX Pharma Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Seizures.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 18, 2022
Lead Product(s) : Brivaracetam
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : GX Pharma Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Felodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Kangqi Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Felodipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Felodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Kangqi Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Modified-Release Tablets 800 mg
Details : Ibuprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chronic Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2022